Expression and Prognostic Value of PIK3CA, VEGF, IL-8, IL-10, and RIP2 in Diffuse Large B-Cell Lymphoma. 2022

Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
Department of Hematology, Affiliated Hospital of Hebei Engineering University, Handan, Hebei, China.

To explore clinical features and prognostic value of vascular endothelial growth factor (VEGF), interleukin (IL) 8, IL-10, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and receptor-interacting protein-2 (RIP2) in diffuse large B-cell lymphoma (DLBCL). A total of 68 DLBCL patients admitted to the Affiliated Hospital of Hebei Engineering University from January 2017 to June 2021 were included in this retrospective analysis. Serum VEGF was detected by enzyme-linked immunosorbent assay, serum IL-8 and IL-10 were detected by chemiluminescent enzyme immunoassay, and expression of PIK3CA and RIP2 in tumors was detected by immunohistochemistry. The correlation between clinical features of DLBCL and tumor-related index were analyzed. Cox regression was conducted to explore risk factors and hazard ratio. The serum level or expressions of VEGF, IL-8, IL-10, and RIP2 were significantly elevated with the increase of Ann Arbor Stage, International Prognostic Index (IPI) scores, Eastern Cooperative Oncology Group (ECOG) scores, serum lactate dehydrogenase (LDH) level, and the number of extranodal sites (all P < 0.05). Beside, these serum indexes were significantly higher in patients with the presence of extranodal involvement and germinal center B-cell (GCB), but significantly lower in patients with the presence of bone marrow involvement (all P < 0.05). Cox regression analysis for overall survival revealed that high expression of VEGF, high level of serum IL-8, serum IL-10, and RIP2, Ann Arbor Stage (III-IV), number of extranodal sites (>1), serum LDH level (≥245 U/L), IPI scores (3-5), ECOG scores (≥2), and bone marrow involvement were independent risk factors for the prognosis of DLBCL patients (all P < 0.05). The serum levels of VEGF, IL-8, and IL-10, as well as the expression of RIP2 and PIK3CA in tumor tissues, were highly correlated to clinical features of DLBCL, and high expression level of these indexes may have adverse effects for the prognosis of DLBCL patients.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016209 Interleukin-8 A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells. CXCL8 Chemokine,Chemokine CXCL8,Chemotactic Factor, Macrophage-Derived,Chemotactic Factor, Neutrophil, Monocyte-Derived,IL-8,Neutrophil-Activating Peptide, Lymphocyte-Derived,Neutrophil-Activating Peptide, Monocyte-Derived,AMCF-I,Alveolar Macrophage Chemotactic Factor-I,Anionic Neutrophil-Activating Peptide,Chemokines, CXCL8,Chemotactic Factor, Neutrophil,Granulocyte Chemotactic Peptide-Interleukin-8,IL8,Monocyte-Derived Neutrophil Chemotactic Factor,Neutrophil Activation Factor,Alveolar Macrophage Chemotactic Factor I,Anionic Neutrophil Activating Peptide,CXCL8 Chemokines,CXCL8, Chemokine,Chemokine, CXCL8,Chemotactic Factor, Macrophage Derived,Chemotactic Peptide-Interleukin-8, Granulocyte,Granulocyte Chemotactic Peptide Interleukin 8,Interleukin 8,Lymphocyte-Derived Neutrophil-Activating Peptide,Macrophage-Derived Chemotactic Factor,Monocyte-Derived Neutrophil-Activating Peptide,Neutrophil Activating Peptide, Lymphocyte Derived,Neutrophil Activating Peptide, Monocyte Derived,Neutrophil Chemotactic Factor,Neutrophil-Activating Peptide, Anionic,Peptide, Anionic Neutrophil-Activating
D016403 Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. Diffuse Large B-Cell Lymphoma,Diffuse, Large B-Cell, Lymphoma,Histiocytic Lymphoma, Diffuse,Lymphoma, Histiocytic, Diffuse,Diffuse Large-Cell Lymphoma,Histiocytic Lymphoma,Large Lymphoid Lymphoma, Diffuse,Large-Cell Lymphoma, Diffuse,Lymphoma, Diffuse Large-Cell,Lymphoma, Histiocytic,Lymphoma, Large Cell, Diffuse,Lymphoma, Large Lymphoid, Diffuse,Lymphoma, Large-Cell, Diffuse,Diffuse Histiocytic Lymphoma,Diffuse Histiocytic Lymphomas,Diffuse Large B Cell Lymphoma,Diffuse Large Cell Lymphoma,Diffuse Large-Cell Lymphomas,Histiocytic Lymphomas,Large Cell Lymphoma, Diffuse,Lymphoma, Diffuse Histiocytic,Lymphoma, Diffuse Large Cell
D016753 Interleukin-10 A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein. IL-10,CSIF-10,Cytokine Synthesis Inhibitory Factor,IL10,Interleukin 10
D042461 Vascular Endothelial Growth Factor A The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced. Vascular Endothelial Growth Factor,Vascular Endothelial Growth Factor-A,GD-VEGF,Glioma-Derived Vascular Endothelial Cell Growth Factor,VEGF,VEGF-A,Vascular Permeability Factor,Vasculotropin,Glioma Derived Vascular Endothelial Cell Growth Factor,Permeability Factor, Vascular
D058534 Class I Phosphatidylinositol 3-Kinases A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits. Phosphatidylinositol 3-Kinase, Class I,Class I Phosphatidylinositol 3-Kinase,Class I Phosphatidylinositol 3 Kinase,Class I Phosphatidylinositol 3 Kinases,Phosphatidylinositol 3 Kinase, Class I

Related Publications

Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
April 2002, Leukemia & lymphoma,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
January 2016, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
February 2018, Zhongguo shi yan xue ye xue za zhi,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
January 2008, Tumori,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
January 2012, Applied immunohistochemistry & molecular morphology : AIMM,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
October 2020, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
January 2022, OncoTargets and therapy,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
December 2015, Zhongguo shi yan xue ye xue za zhi,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
February 2012, Zhongguo shi yan xue ye xue za zhi,
Na Shen, and Yanfang Yu, and Ruiying Zhang, and Ying Guo, and Mei Liu, and Mengtian Tan, and Jianxia Liu, and Jing Bai, and Li Li, and Keyu Liu, and Ran Wang, and Jinglan He
February 2012, Clinical lymphoma, myeloma & leukemia,
Copied contents to your clipboard!